Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 29;29(155):190051.
doi: 10.1183/16000617.0051-2019. Print 2020 Mar 31.

Is bronchiectasis really a disease?

Affiliations

Is bronchiectasis really a disease?

Michal Shteinberg et al. Eur Respir Rev. .

Erratum in

Abstract

The definition of a disease requires that distinguishing signs and symptoms are present that are common, and that the constellation of signs and symptoms differentiate the condition from other causes. In bronchiectasis, anatomical changes, airways inflammation and airway infection are the distinguishing features that are common to this disease. However, bronchiectasis is a heterogenous disease: signs and symptoms are shared with other airway diseases, there are multiple aetiologies and certain phenotypes of bronchiectasis have distinct clinical and laboratory features that are not common to all people with bronchiectasis. Furthermore, response to therapeutic interventions in clinical trials is not uniform. The concept of bronchiectasis as a treatable trait has been suggested, but this may be too restrictive in view of the heterogeneity of bronchiectasis. It is our opinion that bronchiectasis should be defined as a disease in its own right, but one that shares several pathophysiological features and "treatable traits" with other airway diseases. These traits define the large heterogeneity in the pathogenesis and clinical features and suggest a more targeted approach to therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Shteinberg reports grants, personal fees and other funding from GSK, grants and other funding from Novartis, other funding from Actelion, grants from Trudell pharma, personal fees from Astra Zeneca and Horizon Pharma, speakers fees from Teva, other from Rafa, and personal fees and other funding from Boehringer Ingelheim, outside the submitted work. Conflict of interest: P.A. Flume reports grants and personal fees from Bayer Healthcare AG and Insmed, grants from Novoteris, and personal fees from Eloxx Pharmaceuticals and Horizon Pharma, outside the submitted work. Conflict of interest: J.D. Chalmers reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Grifols/Aradigm and Insmed, personal fees from Zambon, and personal fees from Novartis, Bayer, Napp and Savara, outside the submitted work.

References

    1. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: past, present, and future. J Int Neuropsychol Soc 2017; 23: 818–831. - PMC - PubMed
    1. Scully JL. What is a disease? EMBO Rep 2004; 5: 650–653. - PMC - PubMed
    1. Marketos SG, Ballas CN. Bronchial asthma in the medical literature of Greek antiquity. J Asthma 1982; 19: 263–269. - PubMed
    1. Sakula A. R T H Laënnec 1781–1826 his life and work: a bicentenary appreciation. Thorax 1981; 36: 81–90. - PMC - PubMed
    1. Quint JK, Millett ERC, Joshi M, et al. . Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186–193. - PMC - PubMed

LinkOut - more resources